Home | About | Contact

Inside Deal: Brink Ten Paid for 9,800 Shares of Accelerate Diagnostics Inc (NASDAQ:AXDX)

Brink Ten Insider Buy The director of Accelerate Diagnostics Inc, Brink Ten, has just obtained - 9,800 shares of the corporation he’s leading and operating - coming to a cumulative purchase value of $149,352 US Dollars (this based on average share price of $15.2). The Form 4 was unveiled in a filing dated October 1, […]

News Editors : -- 3 October 2015 09:54

Brink Ten Insider Buy

The director of Accelerate Diagnostics Inc, Brink Ten, has just obtained - 9,800 shares of the corporation he’s leading and operating - coming to a cumulative purchase value of $149,352 US Dollars (this based on average share price of $15.2). The Form 4 was unveiled in a filing dated October 1, 2015 with the SEC. The probability of this acquisition remaining unseen is very low, with the director right now having 9,800 shares — that is 0.02% of the market cap of the Company.

Accelerate Diagnostics Inc Sentiment and Fundamentals

Over the last 200 days, the stock price of Accelerate Diagnostics Inc has crashed 8.74% and has strong and smooth bearish downtrend. We rate Accelerate Diagnostics Inc “NEUTRAL”, even though Brink Ten made an insider stock trade, because our trend following model is not flashing Buy.

As famous stock traders including Hugh Hendry claimed, best returns are made through a combination of technical and fundamental analysis. This is definitely not the case with this company.

Institutional Ownership

Data gathered from SEC filings, disclose that 83 hedge funds and other institutions own shares in Accelerate Diagnostics Inc. In Q2 2015, the firm had 22.31% institutional ownership. That is a high interest. They increased by 1.47 million the total shares they hold. As of that quarter these stock owners owned 9.98 million shares. There were 16 funds that created new positions and 22 funds that added to their positions. A total of 4 funds closed their positions in Accelerate Diagnostics Inc and 26 reduced their holdings.

Obermeyer Wood Investment Counsel Lllp had the greatest investment with ownership of 276,549 shares as of Q2 2015 for 0.61% of the fund’s portfolio. Birchview Capital Lp is another bullish institutional manager having 2.07 million shares of the company or 28.55% of their stocks portfolio. The stock is also 33.15% of the fund’s AUM. Moreover Stuart Weisbrod’s Iguana Healthcare Management Llc have 2.20% of their stock portfolio invested in the company’s market cap for 270,000 shares. Selkirk Management Llc disclosed it had acquired a stake worth 2.94% of the fund’s stock portfolio in Accelerate Diagnostics Inc. The New York-based fund Miura Global Management Llc is also an optimist about the company’s stock, with ownership of 600,000 shares or 0.98% of their stock portfolio.

Accelerate Diagnostics NASDAQ:AXDX Firm Profile

Accelerate Diagnostics, Inc. is an in-vitro diagnostics company providing solutions to improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. The Company is focused on reducing the failure rate of initial antibiotic drug therapy by shortening lab turnaround time to approximately five hours, rather than the two to three days required to deliver identification and susceptibility results. It has developed a diagnostic platform, the Accelerate ID/AST System (the ID/AST System), intended for the rapid diagnosis of infectious pathogens. The ID/AST System utilizes genotypic technology to identify (ID) infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. Accelerate Diagnostics UK Limited is a subsidiary of the Company.

Company Website: Accelerate Diagnostics

Accelerate Diagnostics Inc has 73 employees. Now its market value is: $723.60 million and it has 44.72 million shares outstanding. Now there are 35.38% shareholders and the institutional ownership is 35.38%. Accelerate Diagnostics Inc was incorporated in Delaware on 2012-12-24. The stock closed at $16.18 yesterday and it had average 2 days volume of 91756 shares. It is up from the 30 days average shares volume of 67176. Accelerate Diagnostics Inc has a one year low of $14.77 and a one year high of $31.24. The current price is below the 200 days SMA.

Brink Ten is also Vice President of Stericycle Inc, director of Fenix Parts, Inc.

Related Articles
The Insider and President Identification Solns of Brady Corp (NYSE:BRC), Russell Shaller, Bought 1,000 Shares How Will RWE AG (NYSE:RWEOY) Stock React To Societe Generale’s Upgrade to Hold from Sell? Schroders PLC (UNKNOWN:SHNWF) Rating Upgraded at Numis to Buy Insider Transaction: Pioneer Power Solutions, Inc. (NASDAQ:PPSI)’s President - Jefferson Electric - Thomas Klink Obtained 2,745 shares Sienna Senior Living Inc (TSE:SIA) Had Its TP Increases by Analysts at Canaccord Genuity to $17.25 Teck Resources (TSE:TCK.B) Rating Increased by CIBC World Markets to “Sector Outperformer” with $16.00 Target Professional Analysts at HSBC Securities Lowered Telekom Austria (UNKNOWN:TKAGY) from “Buy” to “Hold” Rating David Tesler, Pioneer Power Solutions, Inc. (NASDAQ:PPSI)’s insider Obtained 3,750 Shares Wedbush Reiterated Twitter Inc (NASDAQ:TWTR) As Neutral; Has PT Of $30.00 Pioneer Power Solutions, Inc. (NASDAQ:PPSI)’s director Jonathan Tulkoff Acquired 10,000 Shares of the Company State National Cos (SNC) Stock: JMP Securities Initiates Coverage with Mkt Outperform Rating Twitter (NYSE:TWTR) “Neutral” Rating Reconfirmed by Analysts at Wedbush; The Price Target is $30.0 Deutsche Lufthansa AG (OTCMKTS:DLAKY) Rating Upgraded at HSBC Securities to “Buy” How Will Johnson Controls (NYSE:JCI) Stock React To Nomura’s Upgrade to “Buy” from “Neutral”? Realogy (NYSE:RLGY) Improved by Citigroup to Neutral from Neutral Rating Researchers at Societe Generale Upped RWE AG (OTCMKTS:RWEOY) from “Sell” to “Hold” Rating Schroders plc (OTCMKTS:SHNWF) Rating Outlook Improved by Analysts at Numis to “Buy” TreeHouse Foods (NYSE:THS) Rating was Upped by Research Analysts at BofA Merrill from Neutral to Buy. The Target Price is to $88 EU: Anglo American (OTCMKTS:AAUKY) Stock Rating Downgraded to Sector Underperform by CIBC. Lost Its Sector Perform Rating New York: Astoria Fincl (NYSE:AF) Rating Outlook Decreased to Hold at Sandler O’Neill. Lost Its Buy Rating
Fallow us
Real Time Web Analytics